News Blog Fact Check Press Release Jobs Event Product FAQ Local Business Lists Live Music Recipe

Aurobindo Pharma shares in focus on Monday after US FDA classifies Eugia Unit-III facility as OAI

Aurobindo Pharma shares will remain in focus after its subsidiary Eugia Pharma Specialities received an OAI classification from the US FDA for its Unit-III facility in Telangana. Read details.

Published on



Aurobindo Pharma shares are expected to remain in focus on Monday after the company announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., received an Official Action Indicated (OAI) classification from the United States Food and Drug Administration (US FDA) following an inspection of its manufacturing facility in Telangana.

The development relates to Eugia’s Unit-III formulation manufacturing facility located in Pashamylaram, Telangana. The US FDA conducted an inspection at the facility between January 27 and February 6, 2026. Following the inspection, the regulator issued 11 observations and subsequently classified the inspection outcome as OAI.

US FDA Issues OAI Classification for Eugia Unit-III

An Official Action Indicated (OAI) classification is assigned when the US FDA identifies significant regulatory compliance concerns that may require corrective actions by the company. Such classifications generally indicate that the regulator believes the observed issues warrant official regulatory follow-up.

The inspection of Eugia Unit-III concluded with 11 observations, which were reviewed by the US FDA before assigning the OAI status to the facility.

No Impact on Financials or Operations

Despite the regulatory classification, Aurobindo Pharma clarified that the OAI status will not have any impact on the company’s financial performance or ongoing operations.

The pharmaceutical major stated that business activities continue as usual and that there is no material effect on production or commercial operations resulting from the FDA’s classification.

Company Reiterates Quality Commitment

Aurobindo Pharma emphasized its commitment to maintaining high manufacturing and quality standards across all its global facilities. The company said it remains focused on regulatory compliance and product quality while addressing observations raised by health authorities.

The company also assured investors and stakeholders that it would continue to keep stock exchanges informed regarding any material developments related to the matter.

Want to engage with this content?

Like, comment, or share this article on our main website for the full experience!

Go to Main Website for Full Features

Newsdesk

Stock Market & Business News Writer

Business Desk delivers the latest updates on stocks, financial markets, company earnings and major corporate announcements across India.

More by this author →

Published by · Editorial Policy

NNN Buzz: Latest News, Viral Stories & Lucknow Breaking UpdatesStay updated with NNN Buzz for breaking news, trending stories, entertainment, technology, sports, business, lifestyle, and viral updates from India and around the world.

👉 Read Full Article on Website